TY - JOUR T1 - The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - 1930 AU - Dong Il Park AU - Sun Young Kim AU - Ju Ock Kim AU - Sung Soo Jung AU - Hee Sun Park AU - Jae Young Moon AU - Chae Uk Chung AU - Jeong Eun Lee Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/1930.abstract N2 - Introduction: We evaluated the prognostic value of tumor shrinkage rate (TSR) for PFS in patients with NSCLC receiving gefitinib treatment.Patients and Methods: We performed a retrospective analysis of 85 patients with NSCLC who achieved a stable disease or better response at the first evaluation of treatment response after receiving a 2-month course of gefitinib. We calculated TSR by measuring the longest and perpendicular diameter of the main mass on CT before and after gefitinib therapy.Results: There was a significant positive correlation between the TSR and PFS (R=0.373, p=0.010).In addition, a simple linear regression analysis showed that the TSR might be an indicator for the PFS (β±SE (standard error) 244.54±66.79, p=0.001). On multivariate regression analysis, both the TSR (β±SE 158.38±0.98, p=0.029) and adenocarcinoma (β±SE 135.37±47.07, p=0.005) were independent prognostic factors for PFS.View this table:Multivariate linear regression analyses of variables for progression-free survivalConclusion: Our results showed that the TSR might be an early prognostic indicator for PFS in patients receiving EGFR-TKI therapy. ER -